Biophysical Characterization of Proteins in Developing Biopharmaceuticals

Damian J. Houde is Professor at the Department of Chemistry and Chemical Biology at the Northeastern University in Boston, MA. He teaches undergraduate and graduate level chemistry, biochemistry courses, and bioanalytical biochemistry. Further he is scientist, analytical development at Biogen Idec, Inc. in Cambridge, MA. He performs detailed biochemical and biophysical characterization of protein biopharmaceuticals (primarilymonoclonal antibodies and Fc-fusion proteins) for structure activity relationship studies, investigates the conformation, dynamics, and interactions (epitope mapping) of protein biopharmaceuticals, with hydrogen-deuterium exchange mass spectrometry, assesses, develops, and evaluates new biochemical and biophysical protein characterization tools, coordinates and manages external academic (Northeastern University and University of Mass at Amherst) and internal research collaborations, manages and maintains mass spectrometry instrumentation, and conducts method transfers to QC. In 2009 he received the Douglas and Irena DeVivo Award (Northeastern University), in 2008 the Biogen IDEC Technology Investment Award, in 2008 the Biogen IDEC Technology Investment Award, Outstanding presentation, and in 2007 the Biogen IDEC Technology Investment Award Steven A. Berkowitz is a principal investigator in the department of analytical development at Biogen Idec, Inc. in Cambridge MA. His technical areas of expertise are concentrated in the separation sciences and the physical sciences associated with the characterization of biopolymers and synthetic polymers where he has over 40 peer reviewed publication and has presented numerous talks and posters at a wide range of technical meetings. Much of Dr. Berkowitz’s work has centered on assessing the physico-chemical properties, micro-heterogeneity and aggregation properties of biopharmaceuticals using light scattering, analytical ultracentrifugation, chromatography, electrophoresis, and various forms of spectroscopy. His present responsibilities are now focused on providing biophysical information on the higher-order structure and structural dynamics of biopharmaceuticals and the development and evaluation of analytical tools such as H/DX-MS and NMR to support this area. Dr. Berkowitz received a B.S. degree in Biology from Fairleigh Dickinson University and a Ph.D. degree in Biochemistry from New York University. He then spent several years as a post-doctoral fellow at Yale University and the NIH. After his post-doctoral work Dr. Berkowitz held various positions at Celanese Research Company, J.T. Baker, and Lederle Laboratories before taking his present position at Biogen Idec.

• I: Proteins and Biophysical Characterization in the Biopharmaceutical Industry1. The Complexity of Protein Structure and the Challenges it Poses in Developing Biopharmaceuticals2. Biophysical Characterization and Its Role in the Biopharmaceutical Industry3. Biopharmaceutical Industry's Biophysical ToolboxII: The Selected Biophysical Tools in the Biopharmaceutical Industry4. An Introduction and Hierarchical Organization of the Biophysical Tool5. The Value of UV, Fluorescence, and FTIR Spectroscopy in Biopharmaceutical Development6. Circular Dichroism Spectroscopy for Protein Characterization: Biopharmaceutical Applications7. Size-Exclusion Chromatograph (SEC) in Biopharmaceutical Process Development8. Scattering Techniques for the Characterization of Biopharmaceuticals9. Characterizing Biopharmaceuticals using Analytical Ultracentrifugation10. Sub-visible and Visible Particle Analysis in Biopharmaceutical Research and Development11. Differential Scanning Calorimetry in the Biopharmaceutical Sciences12. Biophysical Mass Spectrometry for Biopharmaceutical Process Development: Focus on Hydrogen/Deuterium Exchange13. One- and Two-Dimensional NMR Techniques for Biopharmaceuticals14. Use of Chromatography and Electrophoresis for indirectly assessing Biophysical CharacterizationIII: Concluding Remarks on the Biophysical Characterization of Biopharmaceuticals15. Biophysically Characterization of very large Biopharmaceuticals16. Statistical Analysis of Biophysical Characterization Data17. Biopharmaceutical Developability18. Technical Decision-making dealing with Biophysical Characterization Data19. Biophysical Characterization: An Integral Part of the "Totality of the Evidence" Concept